🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Clinical Trials in China / NCT06232395
Recruiting Observational

Early Detection and Post-operative Monitoring of Gastric Cancer

NCT06232395 · tracked via the Priya Life Science China tracker
Sponsor
Suzhou Huhu Health & Technology Inc.
Phase
Observational
Started
2024-02-18
Last updated
2025-06-06

Condition(s) studied

Gastric Cancer

Investigational drug(s) / intervention(s)

DNA test

DNA test: circulating DNA test

Study summary

This study is to determine the performance of non-invasive new multi-target biomarkers in the early detection and post-operative monitoring of gastric cancer.

Eligibility

Sex
ALL
Min age
18 Years
Max age
Healthy volunteers
Accepted
Inclusion Criteria: 1. Subject age over 18. 2. Subject has stomach discomfort, and seek medical attention at the Gastric Surgery Department of our center. 3. Subject has or will have gastroscopy and/or pathological examination results at this center. 4. Subject must be able to fully understand the informed consent form and be able to personally sign it. Exclusion Criteria: 1. Subject has serious heart, liver, kidney dysfunction, or mental illness. 2. Subject diagnosed previously with any kind of malignant tumor. 3. Subject is known to be infected with HIV or other related diseases (considering interference from the use of immune drugs). 4. Subject is receiving targeted drugs, immunosuppressants, immunomodulators, and biological therapies. 5. Researchers believe that subject is not suitable for enrollment. 6. Subject can not supply sufficient sample to complete this experiment.

Primary outcome measure(s)

Trial sites (2)

FacilityCityRegionStatus
Fudan University Shanghai Cancer Center. Shanghai Shanghai Municipality Recruiting
Fudan University Shanghai Cancer Center. Shanghai Shanghai Municipality Recruiting

More Suzhou Huhu Health & Technology Inc. trials in China

Other trials for the same condition

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT06232395 on ClinicalTrials.gov ↗ ← All trials in China